Swiss National Bank’s Apellis Pharmaceuticals APLS Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | – | Sell |
-149,500
| Closed | -$6.01M | – | 2309 |
|
|
2026
Q1 | $6.01M | Hold |
149,500
| – | – | ﹤0.01% | 1255 |
|
|
2025
Q4 | $3.76M | Buy |
149,500
+3,300
| +2% | +$77.4K | ﹤0.01% | 1518 |
|
|
2025
Q3 | $3.31M | Buy |
146,200
+2,400
| +2% | +$56K | ﹤0.01% | 1572 |
|
|
2025
Q2 | $2.49M | Buy |
143,800
+11,200
| +8% | +$207K | ﹤0.01% | 1665 |
|
|
2025
Q1 | $2.9M | Sell |
132,600
-11,100
| -8% | -$307K | ﹤0.01% | 1558 |
|
|
2024
Q4 | $4.59M | Sell |
143,700
-10,400
| -7% | -$313K | ﹤0.01% | 1389 |
|
|
2024
Q3 | $4.44M | Sell |
154,100
-600
| -0.4% | -$22.2K | ﹤0.01% | 1399 |
|
|
2024
Q2 | $5.93M | Buy |
154,700
+14,400
| +10% | +$652K | ﹤0.01% | 1163 |
|
|
2024
Q1 | $8.25M | Sell |
140,300
-22,100
| -14% | -$1.41M | 0.01% | 1012 |
|
|
2023
Q4 | $9.72M | Sell |
162,400
-16,800
| -9% | -$852K | 0.01% | 902 |
|
|
2023
Q3 | $6.82M | Buy |
179,200
+3,500
| +2% | +$154K | 0.01% | 1096 |
|
|
2023
Q2 | $16M | Sell |
175,700
-15,300
| -8% | -$1.32M | 0.01% | 701 |
|
|
2023
Q1 | $12.6M | Sell |
191,000
-21,200
| -10% | -$1.22M | 0.01% | 762 |
|
|
2022
Q4 | $11M | Buy |
212,200
+10,100
| +5% | +$536K | 0.01% | 868 |
|
|
2022
Q3 | $13.8M | Buy |
202,100
+17,900
| +10% | +$1.06M | 0.01% | 731 |
|
|
2022
Q2 | $8.33M | Buy |
184,200
+3,100
| +2% | +$141K | 0.01% | 1018 |
|
|
2022
Q1 | $9.2M | Buy |
181,100
+12,200
| +7% | +$539K | 0.01% | 1066 |
|
|
2021
Q4 | $7.99M | Buy |
168,900
+35,500
| +27% | +$1.4M | ﹤0.01% | 1148 |
|
|
2021
Q3 | $4.4M | Buy |
133,400
+500
| +0.4% | +$28.1K | ﹤0.01% | 1554 |
|
|
2021
Q2 | $8.4M | Buy |
132,900
+3,100
| +2% | +$160K | 0.01% | 1129 |
|
|
2021
Q1 | $5.57M | Buy |
129,800
+1,600
| +1% | +$75.7K | ﹤0.01% | 1391 |
|
|
2020
Q4 | $7.33M | Sell |
128,200
-8,700
| -6% | -$368K | 0.01% | 1116 |
|
|
2020
Q3 | $4.13M | Buy |
136,900
+2,300
| +2% | +$68.7K | ﹤0.01% | 1293 |
|
|
2020
Q2 | $4.4M | Buy |
134,600
+20,700
| +18% | +$665K | ﹤0.01% | 1222 |
|
|
2020
Q1 | $3.05M | Buy |
113,900
+28,600
| +34% | +$1.02M | ﹤0.01% | 1195 |
|
|
2019
Q4 | $2.61M | Buy |
85,300
+2,200
| +3% | +$60.9K | ﹤0.01% | 1563 |
|
|
2019
Q3 | $2M | Buy |
83,100
+2,000
| +2% | +$55K | ﹤0.01% | 1656 |
|
|
2019
Q2 | $2.06M | Buy |
81,100
+1,700
| +2% | +$34.6K | ﹤0.01% | 1683 |
|
|
2019
Q1 | $1.55M | Buy |
79,400
+16,000
| +25% | +$252K | ﹤0.01% | 1821 |
|
|
2018
Q4 | $836K | Hold |
63,400
| – | – | ﹤0.01% | 2111 |
|
|
2018
Q3 | $1.13M | Buy |
63,400
+34,100
| +116% | +$630K | ﹤0.01% | 2085 |
|
|
2018
Q2 | $645K | Buy |
+29,300
| New | +$673K | ﹤0.01% | 2378 |
|
Other funds holding APLS
Swiss National Bank's APLS Position: Q2 2026 in Review
Swiss National Bank sold out of Apellis Pharmaceuticals (APLS) in Q2 2026, closing a stake of 149,500 shares — an estimated $6.01M sold.
Swiss National Bank first reported a position in APLS in Q2 2018 and held it in 32 quarters. The position peaked at $16M in Q2 2023. 1 fund tracked by Wall St. Rank holds APLS as of Q2 2026.
- Swiss National Bank reported no remaining Apellis Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
- Swiss National Bank sold 149,500 Apellis Pharmaceuticals shares in Q2 2026, an estimated $6.01M.
- Swiss National Bank first reported a position in Apellis Pharmaceuticals in Q2 2018 and held it in 32 quarters.
- Swiss National Bank's Apellis Pharmaceuticals position peaked at $16M in Q2 2023.
- 1 fund tracked by Wall St. Rank held Apellis Pharmaceuticals as of Q2 2026.
Based on Swiss National Bank's 13F filing for Q2 2026, filed 11 Aug 2026.